The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 83 (high attention) · dilution pressure high · listing risk low · governance risk low · runway 0.6 mo · strongest signal: Runway < 6 months (Jun 30, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (runway < 6 months) coexists with live selling machinery (convertible note, pipe, shelf effective, offering (424b)). Base case is a discounted raise; the question is when, not if.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 14, 2026 | ▼ Offering (424B) | 424B3 prospectus supplement 2026-08-14; 4 prior 424B filings in 12m filing | 28 |
| Aug 13, 2026 | ▼ New debt obligation | 8-K Item 2.03 filed 2026-08-13 (accepted 16:41 ET) filing | 27 |
| Aug 12, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-Q (10-Q) filed 2026-08-12 filing | 25 |
| Jul 31, 2026 | ▼ Shelf effective | EFFECT notice 2026-07-31 filing | 21 |
| Jul 31, 2026 | · Form 4 burst | 9 Form 4 filings in 30 days filing | 16 |
| Jul 21, 2026 | ▼ Convertible note | “convertible note” language in 8-K (8-K) filed 2026-07-21 filing | 39 |
| Jul 21, 2026 | ▼ PIPE | “pipe” language in 8-K (8-K) filed 2026-07-21 filing | 33 |
| Jul 21, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-07-21 (accepted 07:26 ET) filing | 32 |
| Jul 21, 2026 | ▼ New debt obligation | 8-K Item 2.03 filed 2026-07-21 (accepted 07:26 ET) filing | 27 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~0.6 months runway: liquidity $1,372,758 as of 2026-06-30, burn $28,643,028/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 50 |
| Jun 30, 2026 | ▼ Share count +25% | Shares outstanding 5,002,925 (2026-05-12) -> 7,471,960 (2026-08-12), +49% filing | 35 |
| Jun 30, 2026 | ▼ Cash < current liabilities | Liquidity $1,372,758 vs current liabilities $30,485,441 filing | 21 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →